Uric Acid Degrading Enzymes, Urate Oxidase and Allantoinase, Are Associated with Different Subcellular Organelles in Frog Liver and Kidney

Total Page:16

File Type:pdf, Size:1020Kb

Uric Acid Degrading Enzymes, Urate Oxidase and Allantoinase, Are Associated with Different Subcellular Organelles in Frog Liver and Kidney Journal of Cell Science 107, 1073-1081 (1994) 1073 Printed in Great Britain © The Company of Biologists Limited 1994 Uric acid degrading enzymes, urate oxidase and allantoinase, are associated with different subcellular organelles in frog liver and kidney Nobuteru Usuda1,*, Sueko Hayashi1,†, Satoko Fujiwara2, Tomoo Noguchi2, Tetsuji Nagata3, M. Sambasiva Rao1, Keith Alvares1, Janardan K. Reddy1 and Anjana V. Yeldandi1,‡ 1Department of Pathology, Northwestern University Medical School, Chicago, Illinois 60611, USA 2Department of Biochemistry, Kyushu Dental College, Kokura, Kitakyushu 803, Japan 3Department of Anatomy and Cell Biology, Shinshu University School of Medicine, Matsumoto 390, Japan *Present address: Department of Anatomy and Cell Biology, Shinshu University School of Medicine, Matsumoto 390, Japan †Present address: Kyushu Dental College, Kokura, Kitakyushu 803, Japan ‡Author for correspondence SUMMARY On the basis of differential and density gradient centrifu- found to be the exclusive site of urate oxidase localization. gation studies, the site of the uric acid degrading enzymes, Allantoinase was detected within mitochondria, but not in urate oxidase and allantoinase, in amphibia was previously peroxisomes of hepatocytes or proximal tubular epithe- assigned to the hepatic peroxisomes. Using specific anti- lium. No allantoinase was detected in the mitochondria of bodies against frog urate oxidase and allantoinase, we have nonhepatic parenchymal cells in liver and of the cells lining undertaken an immunocytochemical study of the localiza- the distal convoluted tubules of the kidney. These results tion of these two proteins in frog liver and kidney, and demonstrate that, unlike rat kidney peroxisomes which demonstrate that whereas urate oxidase is present in per- lack urate oxidase, peroxisomes of frog kidney contain this oxisomes, allantoinase is localized in mitochondria. Urate enzyme. Contrary to previous assumptions, these studies oxidase and allantoinase were detected by immunoblot also clearly establish that urate oxidase and allantoinase, analysis in both frog liver and kidney. The subcellular the first two enzymes involved in uric acid degradation, are localization of these two enzymes was ascertained by localized in different subcellular organelles in frog liver Protein A-gold immunocytochemical staining of Lowicryl and kidney. K4M-embedded tissue. Peroxisomes in frog liver parenchy- mal cells and kidney proximal tubular epithelium Key words: urate oxidase, allantoinase, purine metabolism, contained a semi-dense subcrystalloid core, which was peroxisome, mitochondrion INTRODUCTION The loss of urate oxidase activity in humans and hominoid primates, such as chimpanzee, gorilla and orangutan, due to Urate oxidase or uricase (urate: oxygen oxidoreductase, EC nonsense mutations in the urate oxidase gene, results in the 1.7.3.3), an enzyme that catalyzes the oxidation of uric acid to excretion of uric acid (Wu et al., 1989; Yeldandi et al., 1990; allantoin, occupies a pivotal position in the chain of enzymes 1991). In amphibia and fish liver, uric acid is degraded all the responsible for the metabolism of purines (Keilin, 1958). way to urea because all three enzymes, urate oxidase, allan- Degradation of purines to uric acid is common to all species toinase and allantoicase, are present (Takada and Noguchi, but the degradation of uric acid, however, varies from species 1983; Noguchi et al., 1986; Hayashi et al., 1989). to species. For example, bacteria and some marine inverte- In the rat, and in most other mammals that display urate brates degrade purines to uric acid, which is then oxidized to oxidase activity and metabolize uric acid to allantoin, this allantoin by urate oxidase (Keilin, 1958). Hydrolysis of enzyme is associated specifically with the crystalloid core allantoin by allantoinase (EC 3.5.2.5) results in the formation present within the peroxisomes in hepatic parenchymal cells of allantoic acid for further metabolism by allantoicase (EC (De Duve and Baudhuin, 1966; Shnitka, 1966; Tsukada et al., 3.5.3.4) to yield urea. The enzyme urease (EC 3.5.1.5) then 1966; Lata et al., 1977; Tolbert, 1981; Usuda et al., 1988a,b; converts urea to ammonia and carbon dioxide. Most mammals, Alvares et al., 1992). Allantoin generated within the peroxi- with the exception of human and hominoid primates, contain some in mammalian hepatocytes is excreted in urine, but the urate oxidase in their liver (Keilin, 1958; Freidman et al., 1985) precise mechanism of allantoin transport out of the peroxi- and excrete allantoin as the end product of purine metabolism, some remains unclear. In amphibia and fish liver, the as these animals do not contain allantoinase and allantoicase. discovery of the presence of all three enzymes of the uric acid 1074 N. Usuda and others degradation pathway led to studies on their subcellular distri- Immunocytochemical labeling bution (Scott et al., 1969; Visentin and Allen, 1969). For immunocytochemical localization, thin sections were incubated Following differential and density gradient centrifugation pro- on drops of 0.5 M Tris-HCl, pH 7.5, containing 0.05% Triton X-100, cedures, it was reported that urate oxidase, allantoinase and 5 mg/ml bovine serum albumin and 0.15 M NaCl for 1 hour. Subse- allantoicase are associated with the peroxisome (Visentin and quently, the sections were transferred onto drops of antibody solution Allen, 1969). The subcellular compartmentalization of these (1:1000 dilution of antiserum in 0.05 M Tris-HCl, pH 7.5, containing three enzymes within hepatic peroxisomes thus apparently 0.05% Triton X-100, 5 mg of bovine serum albumin and 0.15 M served to optimize the metabolic degradation of uric acid to NaCl) and incubated for 4 hours. They were then washed several urea (Hayashi et al., 1989). Recent subcellular fractionation times with 0.05 M Tris-HCl buffer containing 0.1% Triton X-100 and studies of liver demonstrated that marine fishes, such as 0.15 M NaCl. Protein A-gold labeling, using 15 nm size gold particles, (EY Laboratories) was carried out as previously described (Bendayan sardine and mackerel, contain allantoinase both in the perox- and Reddy, 1982; Bendayan et al., 1983). After counterstaining with isome and cytosol, whereas in fresh water fishes (e.g carp, uranyl acetate and lead citrate, the sections were examined in a JEOL bass) this enzyme is found only in the cytosol (Fujiwara et al., 100 CEX electron microscope. A minimum of 20 randomly selected 1989). electron micrographs were obtained from each animal. To demon- In view of the current interest in the evolutionary loss of per- strate the immunocytochemical specificity, control sections were oxisomal enzymes responsible for the degradation of uric acid reacted with nonimmune serum. (Wu et al., 1989; Yeldandi et al., 1990; 1991), the postulated role of uric acid as a potent biological antioxidant (Ames et al., Immunoperoxidase staining 1981), and the possible implications of the generation of the For the demonstration of allantoinase, 3- to 4-µm thick ethanol- or oxidant H2O2 as a result of uric acid metabolism by urate paraformaldehyde-fixed, paraffin-embedded sections were stained oxidase (De Duve and Baudhuin, 1966), it appeared necessary using the avidin-biotin-peroxidase procedure (Usuda et al., 1991). to confirm visually the peroxisomal localization of urate Briefly, the deparaffinized sections were incubated in normal goat oxidase, allantoinase and allantoicase in the frog liver by serum (1:50 dilution) for 20 minutes and then treated with anti-allan- immunocytochemical localization. Our objective in the present toinase antibodies (1:300 dilution) for 2 hours followed by bio- tinylated goat anti-rabbit IgG (1:100 dilution) for 1 hour, and rabbit study was to localize urate oxidase and allantoinase, the first peroxidase anti-peroxidase complex (1:100 dilution) for 1 hour. two enzymes responsible for uric acid degradation in the liver Antibody solutions were made with 50 mM Tris-HCl, pH 7.5, con- and kidney, using Protein A-gold immunocytochemical local- taining 150 mM NaCl and normal goat serum. Sections were then ization. The results show that urate oxidase is localized exclu- incubated in the medium for peroxidase which contained 0.05% sively to the subcrystalloid core present within the peroxisomes 3,3′-diaminobenzidine tetrahydrochloride and 0.01% H2O2 in 0.05 M of both parenchymal cells of liver and the proximal tubular Tris-HCl, pH 7.2, for 10 minutes, and counterstained with 1% epithelium of kidney. Allantoinase, however, was not methyl green. detectable within the peroxisomes in these cells, but was localized to the mitochondrion. Subcellular fractionation Frogs were fasted overnight and their liver perfused in situ with 0.25 M sucrose under light ether anesthesia. The liver and kidneys MATERIALS AND METHODS were removed, finely chopped and homogenized in 5 vols of 0.25 M sucrose/10 mM Tris-HCl, pH 7.5, using a Potter-Elvehjem tissue Antibodies grinder. The homogenate was centrifuged at 960 g for 10 minutes to remove nuclei and unbroken cells. The supernatant was carefully Urate oxidase and allantoinase were purified from the liver of adult bull decanted and centrifuged at 15,000 g for 20 minutes to separate frogs (Rana catesbeiana) and used to raise polyclonal monospecific anti- crude mitochondrial fraction (De Duve et al., 1955). The crude bodies in rabbits, as previously described (Fujiwara et al., 1987; Noguchi mitochondrial fraction was suspended in 20 ml of 0.25 M et al., 1986). Antibodies against
Recommended publications
  • A Monitoring of Allantoin, Uric Acid, and Malondialdehyde Levels In
    A Monitoring of Allantoin, Uric Acid, and Malondialdehyde Levels in Plasma and Erythrocytes after a 10-Minute Running Activity ROMAN KANĎÁR, XENIE ŠTRAMOVÁ, PETRA DRÁBKOVÁ, JANA KŘENKOVÁ Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic A running title: Allantoin and Uric Acid Levels after Running Activity Correspondence to: Roman Kanďár, Ph.D., Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentska 573, 532 10 Pardubice, Czech Republic Tel.: +420 466037714 Fax: +420 466037068 E-mail: [email protected] Keywords: allantoin, uric acid, oxidative stress, antioxidants, short-term intense exercise 1 Summary Uric acid is the final product of human purine metabolism. It was pointed out that this compound acts as an antioxidant and is able to react with reactive oxygen species forming allantoin. Therefore, the measurement of allantoin levels may be used for the determination of oxidative stress in humans. The aim of the study was to clarify the antioxidant effect of uric acid during intense exercise. Whole blood samples were obtained from a group of healthy subjects. Allantoin, uric acid, and malondialdehyde levels in plasma and erythrocytes were measured using a HPLC with UV/Vis detection. Statistical significant differences in allantoin and uric acid levels during short-term intense exercise were found. Immediately after intense exercise, the plasma allantoin levels increased on the average of two hundred per cent in comparison to baseline. Plasma uric acid levels increased slowly, at an average of twenty per cent. On the other hand, there were no significant changes in plasma malondialdehyde.
    [Show full text]
  • Allantoin-Hydrolyzed Animal Protein Product
    Patentamt JEuropaischesEuropean Patent Office ® Publication number: 0 087 374 Office européen des brevets B1 (Î2) EUROPEAN PATENT SPECIFICATION (45) Dateof publication of patent spécification: 27.05.87 ® Int. Cl.4: A 23 J 3/00, A 61 K 7/48 (§) Application number: 83400376.6 (22) Date of filing: 23.02.83 (54) Allantoin-hydrolyzed animal protein product. (30) Priority: 24.02.82 US 351722 (73) Proprietor: CHARLES OF THE RITZ GROUP LTD. 01.06.82 US 383404 40 West 57th Street 13.12.82 US 449117 New York, NY 10019 (US) (§) Dateof publication of application: (72) Inventor: Puchalski, Eugène 31.08.83 Bulletin 83/35 129 McAdoo Avenue Jersey City New Jersey (US) Inventor: Deckner, George E. (§) Publication of the grant of the patent: 645 Horst Street 27.05.87 Bulletin 87/22 Westfield New Jersey (US) Inventor: Dixon, Richard P. 23 Avondale Lane (§) Designated Contracting States: Aberdeen New Jersey (US) AT BE CH DE FR GB IT Ll LU NL SE Inventor: Donahue, Frances A. 2 Kimberley Court Apt. 16 Middletown New Jersey (US) (58) Références cited: FR-A-2510 563 Y- US-A-3 941722 (74) Représentative: Maiffret, Bernard et al Cû Law Offices of William J. Rezac 49, avenue SOAP, PERFUMERY AND COSMETICS, vol. 49, Franklin D. Roosevelt no. 11, November 1976, pages 481-485. S. B. F-75008 Paris (FR) ^ MECCA: "Uric acid, allantoin and allantoin ^ derivatives" SE1FEN- OLE - FETTE - WACHSE, vol. 97, no. 15, N 1971, pages 533-534. S. B. MECCA: "Neue 00 Allantoin-Derivate fur die kosmetische und O dermatologische Anwendung" C9 Note: Within nine months from the publication of t\the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposopposition to the European patent granted.
    [Show full text]
  • Generated by SRI International Pathway Tools Version 25.0, Authors S
    An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. Gcf_000238675-HmpCyc: Bacillus smithii 7_3_47FAA Cellular Overview Connections between pathways are omitted for legibility.
    [Show full text]
  • The Use of Animal Models in Diabetes Research
    Journal of Analytical & Pharmaceutical Research A Comprehensive Review: The Use of Animal Models in Diabetes Research Abstract Review Article Diabetes, a lifelong disease for which there is no cure yet. It is caused by reduced Volume 3 Issue 5 - 2016 production of insulin, or by decreased ability to use insulin. With high prevalence of diabetes worldwide, the disease constitutes a major health concern. Presently, it is an incurable metabolic disorder which affects about 2.8% of the global Iksula Services Pvt. Ltd, India population. Fifty percent of all people with Type I diabetes are under the age of 20. Insulin-dependent diabetes accounts for 3% of all new cases of diabetes *Corresponding author: Reena Rodrigues, Iksula Services each year. Hence, the search for compounds with novel properties to deal Pvt. Ltd, Mumbai, Maharashtra, India, Tel: 022-25924504; with this disease condition is still in progress. Due to time constrains, the use Email: of experimental models for the disease gives the necessary faster. The current review has attempted to bring together all the reported models, highlighted their Received: November 14, 2016 | Published: December 12, short comings and drew the precautions required for each technique. In Type 1 2016 or Diabetes mellitus, the body is unable to store and use glucose as an energy source effectively. Type 2 or diabetes insipidus is a heterogeneous disorder. In this review article we shall bring light as to how hyperglycemia, glucosuria and hyperlipidemia play an important role in the onset of diabetes. Keywords: Diabetes mellitus; Hyperglycemia; Diabetes insipidus; insulin Abbreviations: STZ: Streptozotocin; DNA: Deoxyribonucleic Acid; NAD: Nicotinamide Adenine Dinucleotide; GTG: Gold research.
    [Show full text]
  • Film Dressings Based on Hydrogels: Simultaneous and Sustained-Release of Bioactive Compounds with Wound Healing Properties
    pharmaceutics Article Film Dressings Based on Hydrogels: Simultaneous and Sustained-Release of Bioactive Compounds with Wound Healing Properties 1, 2,7, 3 2,7 Fabian Ávila-Salas y, Adolfo Marican y, Soledad Pinochet , Gustavo Carreño , Oscar Valdés 3 , Bernardo Venegas 4, Wendy Donoso 4, Gustavo Cabrera-Barjas 5 , Sekar Vijayakumar 6 and Esteban F. Durán-Lara 7,8,* 1 Centro de Nanotecnología Aplicada, Facultad de Ciencias, Universidad Mayor, Huechuraba 8580000, Región Metropolitana, Chile 2 Instituto de Química de Recursos Naturales, Universidad de Talca, Talca 3460000, Maule, Chile 3 Vicerrectoría de Investigación y Postgrado, Universidad Católica del Maule, Talca 3460000, Maule, Chile 4 Department of Stomatology, Faculty of Health Sciences, University of Talca, Talca 3460000, Chile 5 Technological Development Unit (UDT), Universidad de Concepción, Av. Cordillera 2634, Parque Industrial Coronel, Coronel 4191996, Biobío, Chile 6 Nanobiosciences and Nanopharmacology Division, Biomaterials and Biotechnology in Animal Health Lab, Department of Animal Health and Management, Alagappa University, Science Campus 6th Floor, Karaikudi-630004, Tamil Nadu, India 7 Bio and NanoMaterials Lab, Drug Delivery and Controlled Release, Universidad de Talca, Talca 3460000, Maule, Chile 8 Departamento de Microbiología, Facultad de Ciencias de la Salud, Universidad de Talca, Talca 3460000, Maule, Chile * Correspondence: [email protected]; Tel.: +56-71-2200363 These authors contributed equally to this work. y Received: 30 July 2019; Accepted: 26 August 2019; Published: 2 September 2019 Abstract: This research proposes the rational modeling, synthesis and evaluation of film dressing hydrogels based on polyvinyl alcohol crosslinked with 20 different kinds of dicarboxylic acids. These formulations would allow the sustained release of simultaneous bioactive compounds including allantoin, resveratrol, dexpanthenol and caffeic acid as a multi-target therapy in wound healing.
    [Show full text]
  • Yeast Genome Gazetteer P35-65
    gazetteer Metabolism 35 tRNA modification mitochondrial transport amino-acid metabolism other tRNA-transcription activities vesicular transport (Golgi network, etc.) nitrogen and sulphur metabolism mRNA synthesis peroxisomal transport nucleotide metabolism mRNA processing (splicing) vacuolar transport phosphate metabolism mRNA processing (5’-end, 3’-end processing extracellular transport carbohydrate metabolism and mRNA degradation) cellular import lipid, fatty-acid and sterol metabolism other mRNA-transcription activities other intracellular-transport activities biosynthesis of vitamins, cofactors and RNA transport prosthetic groups other transcription activities Cellular organization and biogenesis 54 ionic homeostasis organization and biogenesis of cell wall and Protein synthesis 48 plasma membrane Energy 40 ribosomal proteins organization and biogenesis of glycolysis translation (initiation,elongation and cytoskeleton gluconeogenesis termination) organization and biogenesis of endoplasmic pentose-phosphate pathway translational control reticulum and Golgi tricarboxylic-acid pathway tRNA synthetases organization and biogenesis of chromosome respiration other protein-synthesis activities structure fermentation mitochondrial organization and biogenesis metabolism of energy reserves (glycogen Protein destination 49 peroxisomal organization and biogenesis and trehalose) protein folding and stabilization endosomal organization and biogenesis other energy-generation activities protein targeting, sorting and translocation vacuolar and lysosomal
    [Show full text]
  • Allantoin a Safe and Effective Skin Protectant
    Allantoin A safe and effective skin protectant 1. Overview Allantoin, as a natural compound derived from Symphytum officinale, has long been known for its beneficial effects on skin. It is an active compound with keratolytic, keratoplastic, soothing and healing properties largely used in cosmetic, topical pharmaceutical and veterinary products. Allantoin is an anti-irritating and non-toxic agent listed in United States Pharmacopeia, European Pharmacopoeia, Merck Index and British Pharmacopoeial Codex. FDA recognizes allantoin as a skin protectant active ingredient for over-the-counter (OTC) human use. 2. Chemical structure Structural formula: H O O N H H O N N N H H H Empirical formula: C4H6N4O3 Molecular weight: 158.12 Info ALLANTOIN.doc 1/13 02/03/06 Version 04 3. Codex and names CTFA/JSCI name: Allantoin INCI name: Allantoin EINECS name Urea, (2,5-Dioxo-4-Imidazolidinyl)- CAS number: [97-59-6] EINECS number: 202-592-8 JSCI number: S0016 4. Specifications data Appearance: powder Colour: white Odour: odourless Identification: corresponds to C.T.F.A. IR spectrum Assay: 99.0% min Nitrogen: 35.0% – 35.5% pH (0.5% water solution): 3.5 – 6.5 Loss on drying: 0.2% max Sulphated ash: 0.1% max Sulphate: 200 ppm Chloride: 50 ppm Heavy metals (Pb): less than 10 ppm Glycoluril: less than 0.2% Total viable count: Less than 1000 cfu/g Shelf life: 5 year in original packing The analytical methods are available on request. 5. General description Allantoin is a functional compound with mild keratolytic and keratoplastic action on skin. Although the biochemical mechanism of its keratolytic action has not been yet determined, allantoin soften and loosen keratin by disrupting its structure, thereby facilitating desquamation of the cornified cells on the top layer of skin.
    [Show full text]
  • Table S1. List of Genes Up- Or Down-Regulated in H99 When Bound by 18B7
    Table S1. List of genes up- or down-regulated in H99 when bound by 18B7. Up-regulated Genes Classification CNF03470: Formate dehydrogenase Metabolism CNC03960: Phosphate transporter, putative Metabolism CND00530: Putative urea transporter Secretion CNA02250: Ammonium transporter MEP1 Secretion CNC06440: Inositol 1-phosphate synthase Metabolism CND03490: Chitin deacetylase-like mannoprotein MP98 Cell wall CNA04560: Hypothetical protein Hypothetical CNF02180: Acetyl-CoA carboxylase, putative Metabolism CNJ00690: Uracil permease, putative Secretion CNF02510: Alcohol dehydrogenase, putative Metabolism CNE04360: Fatty acid synthase, alpha subunit-related Metabolism CNM00180: Cyclohydrolase, putative Metabolism CNL03740: AF540951 catalase isozyme P Stress CNE04370: Fatty acid synthase, beta subunit Metabolism CNA01790: Expressed protein Hypothetical CNA05700: Expressed protein Hypothetical CND03840: Vacuole fusion, non-autophagic-related protein, putative Cell wall CNM00980: Hypothetical protein Hypothetical CNI02420: Uricase (Urate oxidase), putative Metabolism CNJ01090: Xylitol dehydrogenase-related Cell wall CNC03430: Alpha-1,6-mannosyltransferase, putative Cell wall CNF04120: Expressed protein Hypothetical CNB01810: Short chain dehydrogenase, putative Metabolism CNJ01200: Hypothetical protein Hypothetical CNA01160: LSDR putative Metabolism CNH03430: Hypothetical protein Hypothetical CNM02410: Putative proteine disulfate isomerase Housekeeping CNG04200: Alpha-amylase, putative Cell wall CNC00920: NADP-dependent glutamate dehydrogenase Metabolism
    [Show full text]
  • Nucleotide Metabolism 22
    Nucleotide Metabolism 22 For additional ancillary materials related to this chapter, please visit thePoint. I. OVERVIEW Ribonucleoside and deoxyribonucleoside phosphates (nucleotides) are essential for all cells. Without them, neither ribonucleic acid (RNA) nor deoxyribonucleic acid (DNA) can be produced, and, therefore, proteins cannot be synthesized or cells proliferate. Nucleotides also serve as carriers of activated intermediates in the synthesis of some carbohydrates, lipids, and conjugated proteins (for example, uridine diphosphate [UDP]-glucose and cytidine diphosphate [CDP]- choline) and are structural components of several essential coenzymes, such as coenzyme A, flavin adenine dinucleotide (FAD[H2]), nicotinamide adenine dinucleotide (NAD[H]), and nicotinamide adenine dinucleotide phosphate (NADP[H]). Nucleotides, such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), serve as second messengers in signal transduction pathways. In addition, nucleotides play an important role as energy sources in the cell. Finally, nucleotides are important regulatory compounds for many of the pathways of intermediary metabolism, inhibiting or activating key enzymes. The purine and pyrimidine bases found in nucleotides can be synthesized de novo or can be obtained through salvage pathways that allow the reuse of the preformed bases resulting from normal cell turnover. [Note: Little of the purines and pyrimidines supplied by diet is utilized and is degraded instead.] II. STRUCTURE Nucleotides are composed of a nitrogenous base; a pentose monosaccharide; and one, two, or three phosphate groups. The nitrogen-containing bases belong to two families of compounds: the purines and the pyrimidines. A. Purine and pyrimidine bases Both DNA and RNA contain the same purine bases: adenine (A) and guanine (G).
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,227,164 Lundmark 45 Date of Patent: Jul
    USOO522.7164A United States Patent (19) 11 Patent Number: 5,227,164 Lundmark 45 Date of Patent: Jul. 13, 1993 54 HAIR TREATMENT COMPOSITION AND 3,954,989 5/1976 Mecca ................................. 424/273 METHOD 3,970,756 7/1976 Mecca ................................. 424/273 4,220,166 9/1980 Newell .................................... 132/7 76 Inventor: Larry D. Lundmark, 2925 84th Ave. 4,220,167 9/1980 Newell .................................... 132/7 North, Brooklyn Park, Minn. 55444 4,296,763 10/981 Priest et al. ............................ 132/7 4,478,853 10/1984 Chaussee ...... ... 424/358 (21) Appl. No.: 743,739 4,514,338 4/1985 Hanck et al. 260/429.9 1ar. 4,602,036 7/1986 Hanck et al. ... 54/494. 22 Filed: Aug. 12, 1991 4,705,681 1/1987 Maes et al. ............................ 424/70 Related U.S. Application Data FOREIGN PATENT DOCUMENTS 63 Continuation of Ser. No. 471,843, Jan. 29, 1990, Pat. 1117539 2/1982 Canada ..............................., 514/390 No. 5,041,285. OTHER PUBLICATIONS 51 int. Cli.............................................. A61K 7/021 w 52 U.S. C. ...................................... 424/401; 424/65; Panthenol in Cosmetics, Ibson Drug & Cosmetic Indus 424/68; 424/70 try 5 pp. May 1974. 58) Field of Search ..................... 424/65, 68, 70,401; Urigacid Allantoin and Allantoin Derivatives Soap 548/105, 308, 311, 318.1; 562/569;564/503, Perfumery and Cosmetics, Mecca Reprint Oct. and (56) References Cited Nov. 1976 Issues. Parts 1 & 2 11 pp. Primary Examiner-Thurman K. Page U.S. PATENT DOCUMENTS Assistant Examiner-D. Colucci 2,761,867 9/1956 Mecca ................................. 260/299 2,898,373 8/1959 Kaul ...............
    [Show full text]
  • Open Matthew R Moreau Ph.D. Dissertation Finalfinal.Pdf
    The Pennsylvania State University The Graduate School Department of Veterinary and Biomedical Sciences Pathobiology Program PATHOGENOMICS AND SOURCE DYNAMICS OF SALMONELLA ENTERICA SEROVAR ENTERITIDIS A Dissertation in Pathobiology by Matthew Raymond Moreau 2015 Matthew R. Moreau Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy May 2015 The Dissertation of Matthew R. Moreau was reviewed and approved* by the following: Subhashinie Kariyawasam Associate Professor, Veterinary and Biomedical Sciences Dissertation Adviser Co-Chair of Committee Bhushan M. Jayarao Professor, Veterinary and Biomedical Sciences Dissertation Adviser Co-Chair of Committee Mary J. Kennett Professor, Veterinary and Biomedical Sciences Vijay Kumar Assistant Professor, Department of Nutritional Sciences Anthony Schmitt Associate Professor, Veterinary and Biomedical Sciences Head of the Pathobiology Graduate Program *Signatures are on file in the Graduate School iii ABSTRACT Salmonella enterica serovar Enteritidis (SE) is one of the most frequent common causes of morbidity and mortality in humans due to consumption of contaminated eggs and egg products. The association between egg contamination and foodborne outbreaks of SE suggests egg derived SE might be more adept to cause human illness than SE from other sources. Therefore, there is a need to understand the molecular mechanisms underlying the ability of egg- derived SE to colonize the chicken intestinal and reproductive tracts and cause disease in the human host. To this end, the present study was carried out in three objectives. The first objective was to sequence two egg-derived SE isolates belonging to the PFGE type JEGX01.0004 to identify the genes that might be involved in SE colonization and/or pathogenesis.
    [Show full text]
  • SUPPY Liglucosexlmtdh
    US 20100314248A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0314248 A1 Worden et al. (43) Pub. Date: Dec. 16, 2010 (54) RENEWABLE BOELECTRONIC INTERFACE Publication Classification FOR ELECTROBOCATALYTC REACTOR (51) Int. Cl. (76) Inventors: Robert M. Worden, Holt, MI (US); C25B II/06 (2006.01) Brian L. Hassler, Lake Orion, MI C25B II/2 (2006.01) (US); Lawrence T. Drzal, Okemos, GOIN 27/327 (2006.01) MI (US); Ilsoon Lee, Okemo s, MI BSD L/04 (2006.01) (US) C25B 9/00 (2006.01) (52) U.S. Cl. ............... 204/403.14; 204/290.11; 204/400; Correspondence Address: 204/290.07; 427/458; 204/252: 977/734; PRICE HENEVELD COOPER DEWITT & LIT 977/742 TON, LLP 695 KENMOOR, S.E., PO BOX 2567 (57) ABSTRACT GRAND RAPIDS, MI 495.01 (US) An inexpensive, easily renewable bioelectronic device useful for bioreactors, biosensors, and biofuel cells includes an elec (21) Appl. No.: 12/766,169 trically conductive carbon electrode and a bioelectronic inter face bonded to a surface of the electrically conductive carbon (22) Filed: Apr. 23, 2010 electrode, wherein the bioelectronic interface includes cata lytically active material that is electrostatically bound directly Related U.S. Application Data or indirectly to the electrically conductive carbon electrode to (60) Provisional application No. 61/172,337, filed on Apr. facilitate easy removal upon a change in pH, thereby allowing 24, 2009. easy regeneration of the bioelectronic interface. 7\ POWER 1 - SUPPY|- LIGLUCOSEXLMtDH?till pi 6.0 - esses&aaaas-exx-xx-xx-xx-xxxxixax-e- Patent Application Publication Dec. 16, 2010 Sheet 1 of 18 US 2010/0314248 A1 Potential (nV) Patent Application Publication Dec.
    [Show full text]